Under the terms of this agreement, Dendritic Nanotechnologies will build chemistries on proprietary Lumera surfaces, focusing efforts on using their expertise and patent holdings in the area of dendrimers.
Lumera will use their proprietary instrument designs and biological systems to test and evaluate the dendrimer-based approaches. It is expected that the combined expertise of Lumera in optically active polymers, defined surfaces and label-free detection systems, and the dendrimer expertise of Dendritic Nanotechnologies, will result in unique performance features and benefits for proteomic applications. Terms of the agreement were not disclosed.
“This research agreement with Lumera is an important milestone for DNT since it represents one of the first commercial applications of our recently announced Priostar dendrimers,” said Robert Berry, DNT’s CEO.